Dupixent CTCL Lawsuits
Reviewed by Mazie Slater’s specialized Dupixent lawyer [David A. Mazie – Managing Partner of Mazie Slater Katz & Freeman]
Have you been diagnosed with Cutaneous T-Cell Lymphoma (CTCL) after taking Dupixent (dupilumab)? Have you wondered what caused your CTCL? If so, you may be entitled to compensation. Contact Mazie Slater to have your potential case evaluated.
Mazie Slater is based in New Jersey, where litigation is likely to be located because Sanofi-Aventis, a New Jersey-based pharmaceutical company, partnered in the development and marketing of the drug Dupixent. The other developer of Dupixent, Regeneron, is located nearby in Tarrytown, New York.
Mazie Slater has extensive experience litigating against pharmaceutical companies, has been appointed to leadership positions, and has actually gone to trial for plaintiffs in large pharmaceutical and medical device litigations.
Atopic Dermatitis and Dupixent
The primary indication for Dupixent is the treatment of Atopic dermatitis (AD), also known as eczema, which is a chronic inflammatory skin condition. It causes red, itchy, scaly patches, flares, and sometimes skin thickening or “lichenification.” AD often appears in childhood but can persist or begin in adulthood. Many patients experience cycles of improvement and worsening. Severe or refractory atopic dermatitis can be difficult to control with topical therapies and may involve systemic inflammation and immune dysregulation.
Dupixent is part of a class of biologic / monoclonal antibody therapies designed to target specific immune pathways driving inflammation, rather than broadly suppressing the immune system. Dupixent is approved for treatment of moderate-to-severe atopic dermatitis (especially when topical treatments are inadequate) as well as other conditions with allergic inflammation (e.g. asthma, chronic rhinosinusitis).
Off-Label Use of Dupixent
Dupixent is also prescribed off- label, meaning for conditions not approved by the FDA. Physicians commonly prescribe Dupixent for the following off-label conditions:
- Alopecia areata
- Chronic pruritus
- Hand and foot eczema
- Lichen planus
- Localized scleroderma
- Lichen simplex chronicus
- Netherton syndrome
Dupixent Cutaneous T-Cell Lymphoma Cancer Risk
As part of the immune system, skin plays a major role in the lymphatic system. Certain cancers of the lymph system are called lymphomas. Cutaneous T-Cell Lymphoma or CTCL, is a type of cancer that originates in the skin. It is one of the non-Hodgkins Lymphoma group of cancers that affects a certain type of white blood cell known as T-cells. In cutaneous T-cell lymphoma, T lymphocytes mutate into cancerous cells that multiply uncontrollably. CTCL may include subtypes of Cutaneous T-cell Lymphoma, including Sezary Syndrome, Mycosis Fungoides, and other T-cell Lymphoma subtypes.
Symptoms of Cutaneous T-Cell Lymphoma include:
- Patches of skin discoloration
- Bumps on your skin that might break open
- Itchy, rash-like discoloration all over your body
- Raised skin rash that might be flaky or itchy
- Hair loss
- Swollen lymph nodes
- Thickened skin on the palms of your hands and the soles of your feet
If you or a loved one has been diagnosed with Cutaneous T-Cell Lymphoma after using Dupixent, you may be entitled to compensation. Contact Mazie Slater Katz & Freeman today for a free consultation to discuss your legal options.
Dupixent Can Cause CTCL
Dupixent was initially viewed as a safer long-term option for many patients with severe Atopic Dermatitis. But over the last few years, reports in the scientific literature have raised concerns that Dupixent may contribute to the development of Cutaneous T-Cell Lymphoma.
Beginning around 2020, researchers and physicians started publishing case reports and clinical studies raising concern about a possible connection between Dupixent (dupilumab) and the development of Cutaneous T-Cell Lymphoma (CTCL). The emerging data suggests that patients treated with Dupixent may face a substantially higher likelihood of developing this rare form of skin cancer compared to those who have not taken the drug. There is also data indicating that Dupixent can cause progression of CTCL as well.
Recent medical analyses indicate that Dupixent use is associated with as much as a 4.5 fold (350%) increase in CTCL risk.
Our investigation shows that the drug manufacturers were aware, or should have been aware, of these potential dangers yet failed to adequately warn patients, physicians, and the broader medical community about the risks. This violates product liability law.
Lawsuits for CTCL After Dupixent Use?
Our Dupixent lawyers can help determine if you have grounds to file a CTCL lawsuit against the manufacturers and sellers of Dupixent and explain what will be needed to win your case. If you were diagnosed with Cutaneous T-Cell Lymphoma (CTCL) after taking Dupixent (dupilumab), contact us to investigate your situation, and discuss your options for a lawsuit.
Frequently Asked Questions about Dupixent & CTCL
-
What is Dupixent?
Dupixent (dupilumab) is a biologic/monoclonal antibody therapy approved to treat moderate-to-severe atopic dermatitis (eczema), asthma, and chronic rhinosinusitis. It works by targeting specific immune pathways that drive inflammation, rather than broadly suppressing the immune system.
-
What is Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-Cell Lymphoma is a type of non-Hodgkin’s Lymphoma that originates in the skin, in which T lymphocytes mutate into cancerous cells that multiply uncontrollably. Subtypes include Mycosis Fungoides and Sézary Syndrome.
-
What is the link between Dupixent and CTCL?
Beginning around 2020, researchers began publishing case reports and clinical studies suggesting a possible connection between Dupixent use and the development of CTCL. Recent medical analyses indicate that Dupixent use may be associated with as much as a 4.5-fold increase in CTCL risk.
-
Did the manufacturers know about the CTCL risk?
Mazie Slater’s investigation indicates that the drug manufacturers were aware, or should have been aware, of these potential dangers but failed to adequately warn patients and physicians — a potential violation of product liability law.
-
Who can file a Dupixent CTCL lawsuit?
Anyone who was diagnosed with CTCL after taking Dupixent may have grounds for a lawsuit. This includes patients who were prescribed Dupixent both for its FDA-approved indications and for off-label uses.
-
Why should I choose Mazie Slater for my Dupixent CTCL case?
Mazie Slater is based in New Jersey, where litigation is likely to be concentrated given that Sanofi-Aventis — one of Dupixent’s developers — is headquartered there. The firm has extensive experience litigating against pharmaceutical companies, including serving in leadership positions and going to trial on behalf of plaintiffs in major pharmaceutical and medical device cases.
